NASDAQ:IMCR

Immunocore Q1 2025 Earnings Results & Report

Immunocore logo
$27.81 -1.07 (-3.70%)
Closing price 04:00 PM Eastern
Extended Trading
$27.79 -0.02 (-0.07%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunocore beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 7, 2025. The company reported EPS of $0.10 versus the -$0.35 consensus estimate, while revenue of $125.13 million topped the $108.82 million estimate by $16.32 million. Revenue increased 33.6% year over year.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Immunocore EPS Results

Actual EPS
$0.10
Consensus EPS
-$0.35
Beat/Miss
Beat by +$0.45
One Year Ago EPS
-$0.49
EPS Beat Rate
5 of last 8 quarters

Immunocore Revenue Results

Actual Revenue
$125.13 million
Expected Revenue
$108.82 million
Beat/Miss
Beat by +$16.32 million
YoY Revenue Growth
+33.60%

Immunocore Q1 2025 Earnings FAQ

Immunocore (NASDAQ:IMCR) reported earnings of $0.10 per share for Q1 2025, beating the consensus estimate of -$0.35. The report was announced on Wednesday, May 7, 2025.

Immunocore reported revenue of $125.13 million for Q1 2025, against a consensus estimate of $108.82 million.

Immunocore Earnings Headlines

Immunocore FY2026 Earnings Forecast Reduced by HC Wainwright
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
See More Immunocore Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email.

About Immunocore

Immunocore (NASDAQ:IMCR) is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach.

The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma. Immunocore is also developing a pipeline of TCR therapies for additional cancers and research programs in infectious and autoimmune diseases.

Founded in 2008 and headquartered in the United Kingdom, Immunocore serves patients and pursues commercial and development activities in multiple markets, including the United States and Europe. Bahija Jallal is the company’s chief executive officer.

View Immunocore Profile